CGEN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.62M

+10.1%

-0.077

+10.71%

1.25M

-45.27%

-0.075

-6.25%

1.25M

-0.56%

-0.075

-6.25%

Estimates Revision

The market is revising Upward the revenue expectations for Compugen Ltd. (CGEN) for FY2025, with the revenue forecasts being adjusted by 9.03% over the past three months. During the same period, the stock price has changed by -2.08%.

Revenue Estimates for FY2025

Revise Upward

+9.03%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.66%

In Past 3 Month

Stock Price

Go Down

-2.08%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

H.C. Wainwright

NULL -> Buy

initiated

2026-01-07

New

Reason

H.C. Wainwright

Price Target

2026-01-07

New

initiated

NULL -> Buy

Reason

H.C. Wainwright initiated coverage of Compugen with a Buy rating and $4 price target. The firm says the company's immuno-oncology pipeline "offers multiple shots on goal." Compugen holds mid-single-digit royalty rights and AstraZeneca estimates peak sales potential of more than $5B, implying a peak royalty stream of over $200M, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Compugen Ltd (CGEN.O) is -5.04, compared to its 5-year average forward P/E of -27.63. For a more detailed relative valuation and DCF analysis to assess Compugen Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.63

Current PE

-5.04

Overvalued PE

19.51

Undervalued PE

-74.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.41

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.50

Undervalued EV/EBITDA

-6.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

39.19

Current PS

28.39

Overvalued PS

160.75

Undervalued PS

-82.37

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CGEN News & Events

Events Timeline

No data

News

4.0

01-07Benzinga

HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target

7.5

2025-12-17PRnewswire

Compugen Agrees with AstraZeneca to Monetize Future Royalties of Rilvegostomig

7.5

2025-12-17Newsfilter

Compugen Secures $65 Million Upfront Payment in AstraZeneca Deal

People Also Watch

Frequently Asked Questions

What is Compugen Ltd (CGEN) stock price today?

The current price of CGEN is 1.88 USD — it has increased 14.63 % in the last trading day.

What is Compugen Ltd (CGEN)'s business?

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

What is the price predicton of CGEN Stock?

What is Compugen Ltd (CGEN)'s revenue for the last quarter?

Compugen Ltd revenue for the last quarter amounts to 1.89M USD, decreased -88.96 % YoY.

What is Compugen Ltd (CGEN)'s earnings per share (EPS) for the last quarter?

Compugen Ltd. EPS for the last quarter amounts to -0.07 USD, decreased -800.00 % YoY.

What changes have occurred in the market's expectations for Compugen Ltd (CGEN)'s fundamentals?

How many employees does Compugen Ltd (CGEN). have?

Compugen Ltd (CGEN) has 74 emplpoyees as of January 09 2026.

What is Compugen Ltd (CGEN) market cap?

Today CGEN has the market capitalization of 175.85M USD.